SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.17 CNY | +0.09% |
|
+0.30% | -7.43% |
| Sales 2024 * | 44.43B 6.14B | Sales 2025 * | 50.5B 6.97B | Capitalization | 55.39B 7.65B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.24B 448M | Net income 2025 * | 4.12B 570M | EV / Sales 2024 * | 1.59 x |
| Net Debt 2024 * | 15.46B 2.14B | Net Debt 2025 * | 17.72B 2.45B | EV / Sales 2025 * | 1.45 x |
| P/E ratio 2024 * |
19
x | P/E ratio 2025 * |
14.8
x | Employees | 40,370 |
| Yield 2024 * |
1.62% | Yield 2025 * |
2.08% | Free-Float | 63.46% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.09% | ||
| 1 week | +0.30% | ||
| 1 month | -2.11% | ||
| 3 months | -6.46% | ||
| 6 months | -17.19% | ||
| Current year | -7.43% |
1 week
22.95
23.40
1 month
22.9524.62
Current year
20.3825.89
1 year
20.3832.08
3 years
20.3891.69
5 years
20.3891.69
10 years
16.5091.69
| Managers | Title | Age | Since |
|---|---|---|---|
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Dong Ming Li
PSD | President | 55 | 20-10-28 |
Yi Fang Wu
CHM | Chairman | 54 | 04-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fang Yao
BRD | Director/Board Member | 54 | 10-04-08 |
Qi Yu Chen
BRD | Director/Board Member | 52 | 94-03-31 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.27% | 2 M€ | -18.79% | - | |
| 1.18% | 4 M€ | -2.96% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 23.17 | +0.09% | 6,103,400 |
| 24-05-30 | 23.15 | +0.22% | 5,418,588 |
| 24-05-29 | 23.1 | -0.43% | 4,630,916 |
| 24-05-28 | 23.2 | -0.22% | 5,811,447 |
| 24-05-27 | 23.25 | +0.65% | 7,387,616 |
End-of-day quote Shanghai S.E., May 30, 2024
More quotes
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities:
- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;
- sale of medical equipments and diagnosis products (17.3%);
- medical and hospital services (10.5%);
- other (0.1%).
China accounts for 72.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-06-26
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
23.17
CNY
Average target price
28.61
CNY
Spread / Average Target
+23.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.43% | 7.65B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.42% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.19% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- 600196 Stock
